AdAlta Limited

Add to watchlist
A$0.155
Last updated:06/11/2021
1AD: AU
AdAlta Limited

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseas… Show more

P/E ratio
-
vs. 0.00x forward

Company has negative earnings per share so P/E ratio is not available.

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2018
2019
2020
2021
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-21.067M
-45.663M
-116.75%
-117.841M
-158.07%
-73.174M
+37.90%
Cashflow
Sum up money going in and out company
-24.251M
-39.143M
-61.41%
-86.825M
-121.81%
11.286M
+113.00%
Total liabilities
All combined debts and obligations
8.692M
19.06M
+119.28%
32.178M
+68.82%
249.594M
+675.67%
Company profile
CEO
Dr. Timothy Charles Oldham B.Sc., L.L.B., BSc(Hons), LLB(Hons), Ph.D.
Market capitalization
Nano (38.00M)